See more : US Masters Residential Property Fund (UMRRF) Income Statement Analysis – Financial Results
Complete financial analysis of BioPlus Acquisition Corp. (BIOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPlus Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Hangcha Group Co., Ltd (603298.SS) Income Statement Analysis – Financial Results
- African Gold Acquisition Corporation (AGAC) Income Statement Analysis – Financial Results
- American Energy Partners, Inc. (AEPT) Income Statement Analysis – Financial Results
- Tokyo Ichiban Foods Co., Ltd. (3067.T) Income Statement Analysis – Financial Results
- Golden Mile Resources Limited (G88.AX) Income Statement Analysis – Financial Results
BioPlus Acquisition Corp. (BIOS)
About BioPlus Acquisition Corp.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 708.90M | 817.20M | 935.60M | 982.20M | 984.10M | 842.20M | 662.60M | 0.00 | 1.64B | 1.33B | 1.40B | 1.20B | 1.15B | 1.07B | 630.50M | 588.80M | 576.60M | 456.60M | 369.80M | 377.40M | 451.10M | 242.30M | 283.20M | 213.90M | 109.30M | 100.00K |
| Cost of Revenue | 1.17M | 0.00 | 465.90M | 547.90M | 670.00M | 721.30M | 723.00M | 570.40M | 437.70M | 0.00 | 1.38B | 1.17B | 1.26B | 1.06B | 1.03B | 957.00M | 562.40M | 520.20M | 506.00M | 403.20M | 334.60M | 347.10M | 421.40M | 239.00M | 278.10M | 213.40M | 106.70M | 0.00 |
| Gross Profit | -1.17M | 0.00 | 243.00M | 269.30M | 265.60M | 260.90M | 261.10M | 271.80M | 224.90M | 0.00 | 260.40M | 157.80M | 142.20M | 137.00M | 119.60M | 116.20M | 68.10M | 68.60M | 70.60M | 53.40M | 35.20M | 30.30M | 29.70M | 3.30M | 5.10M | 500.00K | 2.60M | 100.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 34.28% | 32.95% | 28.39% | 26.56% | 26.53% | 32.27% | 33.94% | 0.00% | 15.89% | 11.87% | 10.14% | 11.44% | 10.38% | 10.83% | 10.80% | 11.65% | 12.24% | 11.70% | 9.52% | 8.03% | 6.58% | 1.36% | 1.80% | 0.23% | 2.38% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.17K | 162.43 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Other Expenses | 1.17M | 0.00 | 189.60M | 220.80M | 197.70M | 465.00M | 35.10M | 40.70M | 13.10M | 4.80M | 27.90M | 1.80M | 96.60M | 2.90M | 6.60M | 36.10M | 3.00M | 1.90M | 500.00K | -200.00K | 1.50M | 7.10M | 4.00M | 0.00 | 26.60M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.17M | 162.43 | 236.90M | 284.10M | 263.70M | 548.60M | 354.50M | 294.70M | 211.60M | 4.80M | 254.20M | 142.40M | 225.70M | 128.20M | 135.80M | 145.40M | 55.80M | 52.50M | 46.40M | 38.30M | 35.40M | 35.10M | 27.10M | 19.10M | 38.20M | 8.00M | 5.30M | 100.00K |
| Cost & Expenses | 1.17M | 162.43 | 702.80M | 832.00M | 933.70M | 1.27B | 1.08B | 865.10M | 649.30M | 4.80M | 1.63B | 1.31B | 1.49B | 1.19B | 1.17B | 1.10B | 618.20M | 572.70M | 552.40M | 441.50M | 370.00M | 382.20M | 448.50M | 258.10M | 316.30M | 221.40M | 112.00M | 100.00K |
| Interest Income | 3.17M | 9.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | -57.40M | -52.10M | -38.20M | -37.30M | -38.50M | 28.20M | 26.07M | 28.31M | -27.60M | -1.90M | -2.70M | -3.30M | -3.00M | -400.00K | -800.00K | -800.00K | -800.00K | -100.00K | 800.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 23.60M | 27.73M | 21.55M | 22.74M | -81.10M | -16.10M | 73.07M | 15.88M | 12.33M | 5.03M | 6.40M | 7.09M | 10.86M | 9.92M | 5.03M | 5.08M | 6.06M | 6.36M | 4.88M | 3.22M | 1.69M | 1.09M | 780.00K | 370.00K | 90.00K | 0.00 |
| EBITDA | -1.17M | 9.49 | -84.90M | -24.97M | -56.15M | -335.76M | -174.60M | -39.00M | 86.37M | 39.39M | -36.67M | 16.63M | -82.50M | 9.39M | -11.44M | -19.98M | 15.73M | 19.48M | 28.66M | 21.36M | 3.98M | 420.00K | 7.69M | -10.11M | -29.62M | -5.73M | -2.21M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -11.98% | -3.06% | -6.00% | -34.18% | -17.74% | -4.63% | 13.03% | 0.00% | -2.24% | 1.25% | -5.88% | 0.78% | -0.99% | -1.86% | 2.49% | 3.31% | 4.97% | 4.68% | 1.08% | 0.11% | 1.70% | -4.17% | -10.46% | -2.68% | -2.02% | 0.00% |
| Operating Income | -1.17M | -162.43 | -108.50M | -52.70M | -77.70M | -358.50M | -93.50M | -22.90M | 13.30M | 23.51M | -49.00M | 11.60M | -88.90M | 2.30M | -22.30M | -29.90M | 10.70M | 14.40M | 22.60M | 15.00M | -900.00K | -2.80M | 6.00M | -11.20M | -30.40M | -6.10M | -2.30M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -15.31% | -6.45% | -8.30% | -36.50% | -9.50% | -2.72% | 2.01% | 0.00% | -2.99% | 0.87% | -6.34% | 0.19% | -1.93% | -2.79% | 1.70% | 2.45% | 3.92% | 3.29% | -0.24% | -0.74% | 1.33% | -4.62% | -10.73% | -2.85% | -2.10% | 0.00% |
| Total Other Income/Expenses | 3.17M | 9.49 | 57.50M | -14.70M | 45.30M | 33.50M | -38.50M | -28.20M | -26.10M | -28.31M | 27.60M | 1.90M | 2.70M | 3.30M | 3.00M | 300.00K | 800.00K | 800.00K | 800.00K | 100.00K | -800.00K | -1.00M | -1.70M | -2.30M | -1.40M | -700.00K | -200.00K | 0.00 |
| Income Before Tax | 2.00M | -152.95 | -51.00M | -67.40M | -32.40M | -325.00M | -132.00M | -51.10M | -12.80M | -4.80M | -21.40M | 13.50M | -86.20M | 5.60M | -19.30M | -29.60M | 11.50M | 15.20M | 23.40M | 15.10M | -1.70M | -3.80M | 4.30M | -13.50M | -31.80M | -6.80M | -2.50M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -7.19% | -8.25% | -3.46% | -33.09% | -13.41% | -6.07% | -1.93% | 0.00% | -1.31% | 1.02% | -6.15% | 0.47% | -1.67% | -2.76% | 1.82% | 2.58% | 4.06% | 3.31% | -0.46% | -1.01% | 0.95% | -5.57% | -11.23% | -3.18% | -2.29% | 0.00% |
| Income Tax Expense | -3.17M | 9.49 | 600.00K | 63.60M | 2.00M | -21.50M | 11.40M | 2.50M | -4.40M | 28.31M | 47.70M | -40.60M | -12.20M | 2.30M | 19.00M | -5.70M | 4.50M | 6.10M | 4.70M | 900.00K | 100.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Net Income | 5.16M | -152.95 | -51.60M | -131.00M | -34.40M | -303.50M | -143.40M | -53.60M | -8.40M | -33.11M | -69.10M | 54.10M | -74.00M | 3.30M | -38.30M | -23.90M | 7.00M | 9.10M | 18.70M | 14.20M | -1.80M | -4.80M | 2.60M | -15.80M | -33.20M | -7.50M | -2.70M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -7.28% | -16.03% | -3.68% | -30.90% | -14.57% | -6.36% | -1.27% | 0.00% | -4.22% | 4.07% | -5.28% | 0.28% | -3.32% | -2.23% | 1.11% | 1.55% | 3.24% | 3.11% | -0.49% | -1.27% | 0.58% | -6.52% | -11.72% | -3.51% | -2.47% | 0.00% |
| EPS | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| Weighted Avg Shares Out | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
| Weighted Avg Shares Out (Dil) | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
BioScrip to Host Second Quarter 2012 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2012 second quarter financial results on Wednesday, August 8, 2012, after the market closes. The Company will host a conference call at 9:00 a.m. Eastern Daylight Time...
BioScrip to Present at Jefferies 2012 Global Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2012 Global Healthcare Conference to be held at the Grand Hyatt in New York City on June 4-7, 2012. Richard M. Smith, President and Chief...
BioScrip to Present at Bank of America Merrill Lynch 2012 Health Care Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference to be held at Encore at the Wynn in Las Vegas, NV on May 15-17, 2012. Richard...
BioScrip Reports 2012 First Quarter Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million. As...
BioScrip Completes Sale of Community Pharmacies and Centralized Specialty and Mail Service Pharmacy to Walgreens
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) (the “Company”) today announced that it has closed the sale of certain assets of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses (the “Transferred Businesses”) to Walgreen Co. (NYSE, NASDAQ:...
Walgreens Completes Acquisition of BioScrip's Community Specialty Pharmacies and Centralized Specialty and Mail Service Pharmacy Businesses
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreen Co. (NYSE: WAG) (NASDAQ: WAG) today announced that it has completed its acquisition of certain assets of BioScrip, Inc.’s (NASDAQ: BIOS) community specialty pharmacies and centralized specialty and mail service pharmacy businesses. The transaction represents a total...
BioScrip to Host First Quarter 2012 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2012 first quarter financial results before the market opens on Wednesday, May 9, 2012, and host a conference call at 8:30 a.m. Eastern Daylight Time (EDT) to...
BioScrip Appoints Hai V. Tran as Senior Vice President, Chief Financial Officer and Treasurer
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) (the “Company”) today announced that Hai V. Tran has been appointed as Senior Vice President, Chief Financial Officer and Treasurer effective May 14, 2012. Mr. Tran will succeed MJ Graves, who has been serving...
BioScrip Reports 2011 Fourth Quarter and Year-End Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2011 fourth quarter and year-end financial results. Fourth quarter revenue was $483.3 million and net income was $6.7 million, or $0.12 per share. Adjusted EBITDA for the fourth quarter was $19.8 million....
BioScrip to Host Fourth Quarter and Full Year 2011 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2011 fourth quarter and full year financial results before the market opens on Friday, March 9, 2012, and host a conference call at 8:30 a.m. Eastern Standard...
Source: https://incomestatements.info
Category: Stock Reports